Cargando…

Validating risk models versus age alone for atrial fibrillation in a young Dutch population cohort: should atrial fibrillation risk prediction be expanded to younger community members?

BACKGROUND: Advancing age is the primary selection criterion for community screening for atrial fibrillation (AF), with selection often restricted to those aged ≥65 years. If multivariable models were shown to have considerable additional value over age alone in predicting AF risk among younger indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Himmelreich, Jelle C L, Harskamp, Ralf E, Geelhoed, Bastiaan, Virdone, Saverio, Lucassen, Wim A M, Gansevoort, Ron T, Rienstra, Michiel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852746/
https://www.ncbi.nlm.nih.gov/pubmed/35173009
http://dx.doi.org/10.1136/bmjopen-2021-057476
_version_ 1784653101188251648
author Himmelreich, Jelle C L
Harskamp, Ralf E
Geelhoed, Bastiaan
Virdone, Saverio
Lucassen, Wim A M
Gansevoort, Ron T
Rienstra, Michiel
author_facet Himmelreich, Jelle C L
Harskamp, Ralf E
Geelhoed, Bastiaan
Virdone, Saverio
Lucassen, Wim A M
Gansevoort, Ron T
Rienstra, Michiel
author_sort Himmelreich, Jelle C L
collection PubMed
description BACKGROUND: Advancing age is the primary selection criterion for community screening for atrial fibrillation (AF), with selection often restricted to those aged ≥65 years. If multivariable models were shown to have considerable additional value over age alone in predicting AF risk among younger individuals, AF screening could be expanded to patients with lower age, but with high AF risk as per a validated risk model. METHODS: We validated risk models CHARGE-AF (Cohorts for Heart and Aging Research in Genomic Epidemiology model for AF) and FHS-AF (Framingham Heart Study model for AF), and risk scores CHA(2)DS(2)-VASc and CHA(2)DS(2)-VA, and presented their predictive abilities for 5-year and 10-year AF risk versus that of age alone in a young Dutch population cohort (PREVEND) free from AF at baseline. We assessed discrimination by the C-statistic and calibration by the calibration plot and stratified Kaplan-Meier plot using survey-weighted Cox models. RESULTS: During 5-year and 10-year follow-up there were n=98 (2.46/1000 person-years) and n=249 (3.29/1000 person-years) new AF cases, respectively, among 8265 participants with mean age 49±13 years. CHARGE-AF and FHS-AF both showed good discrimination for 5-year and 10-year AF (C-statistic range 0.83–0.86) with accurate calibration for 5-year AF, but overestimation of 10-year AF risk in highest-risk individuals. CHA(2)DS(2)-VASc and CHA(2)DS(2)-VA relatively underperformed. Age alone showed similar discrimination to that of CHARGE-AF and FHS-AF both in the overall, young PREVEND cohort and in subgroups for lower age and lower stroke risk. CONCLUSION: Multivariable models accurately discriminate for 5-year and 10-year AF risk among young European community-dwelling individuals. However, their additional discriminatory value over age alone was limited. Selection strategies for primary AF screening using multivariable models should not be expanded to younger individuals.
format Online
Article
Text
id pubmed-8852746
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-88527462022-03-03 Validating risk models versus age alone for atrial fibrillation in a young Dutch population cohort: should atrial fibrillation risk prediction be expanded to younger community members? Himmelreich, Jelle C L Harskamp, Ralf E Geelhoed, Bastiaan Virdone, Saverio Lucassen, Wim A M Gansevoort, Ron T Rienstra, Michiel BMJ Open Cardiovascular Medicine BACKGROUND: Advancing age is the primary selection criterion for community screening for atrial fibrillation (AF), with selection often restricted to those aged ≥65 years. If multivariable models were shown to have considerable additional value over age alone in predicting AF risk among younger individuals, AF screening could be expanded to patients with lower age, but with high AF risk as per a validated risk model. METHODS: We validated risk models CHARGE-AF (Cohorts for Heart and Aging Research in Genomic Epidemiology model for AF) and FHS-AF (Framingham Heart Study model for AF), and risk scores CHA(2)DS(2)-VASc and CHA(2)DS(2)-VA, and presented their predictive abilities for 5-year and 10-year AF risk versus that of age alone in a young Dutch population cohort (PREVEND) free from AF at baseline. We assessed discrimination by the C-statistic and calibration by the calibration plot and stratified Kaplan-Meier plot using survey-weighted Cox models. RESULTS: During 5-year and 10-year follow-up there were n=98 (2.46/1000 person-years) and n=249 (3.29/1000 person-years) new AF cases, respectively, among 8265 participants with mean age 49±13 years. CHARGE-AF and FHS-AF both showed good discrimination for 5-year and 10-year AF (C-statistic range 0.83–0.86) with accurate calibration for 5-year AF, but overestimation of 10-year AF risk in highest-risk individuals. CHA(2)DS(2)-VASc and CHA(2)DS(2)-VA relatively underperformed. Age alone showed similar discrimination to that of CHARGE-AF and FHS-AF both in the overall, young PREVEND cohort and in subgroups for lower age and lower stroke risk. CONCLUSION: Multivariable models accurately discriminate for 5-year and 10-year AF risk among young European community-dwelling individuals. However, their additional discriminatory value over age alone was limited. Selection strategies for primary AF screening using multivariable models should not be expanded to younger individuals. BMJ Publishing Group 2022-02-16 /pmc/articles/PMC8852746/ /pubmed/35173009 http://dx.doi.org/10.1136/bmjopen-2021-057476 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Cardiovascular Medicine
Himmelreich, Jelle C L
Harskamp, Ralf E
Geelhoed, Bastiaan
Virdone, Saverio
Lucassen, Wim A M
Gansevoort, Ron T
Rienstra, Michiel
Validating risk models versus age alone for atrial fibrillation in a young Dutch population cohort: should atrial fibrillation risk prediction be expanded to younger community members?
title Validating risk models versus age alone for atrial fibrillation in a young Dutch population cohort: should atrial fibrillation risk prediction be expanded to younger community members?
title_full Validating risk models versus age alone for atrial fibrillation in a young Dutch population cohort: should atrial fibrillation risk prediction be expanded to younger community members?
title_fullStr Validating risk models versus age alone for atrial fibrillation in a young Dutch population cohort: should atrial fibrillation risk prediction be expanded to younger community members?
title_full_unstemmed Validating risk models versus age alone for atrial fibrillation in a young Dutch population cohort: should atrial fibrillation risk prediction be expanded to younger community members?
title_short Validating risk models versus age alone for atrial fibrillation in a young Dutch population cohort: should atrial fibrillation risk prediction be expanded to younger community members?
title_sort validating risk models versus age alone for atrial fibrillation in a young dutch population cohort: should atrial fibrillation risk prediction be expanded to younger community members?
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852746/
https://www.ncbi.nlm.nih.gov/pubmed/35173009
http://dx.doi.org/10.1136/bmjopen-2021-057476
work_keys_str_mv AT himmelreichjellecl validatingriskmodelsversusagealoneforatrialfibrillationinayoungdutchpopulationcohortshouldatrialfibrillationriskpredictionbeexpandedtoyoungercommunitymembers
AT harskampralfe validatingriskmodelsversusagealoneforatrialfibrillationinayoungdutchpopulationcohortshouldatrialfibrillationriskpredictionbeexpandedtoyoungercommunitymembers
AT geelhoedbastiaan validatingriskmodelsversusagealoneforatrialfibrillationinayoungdutchpopulationcohortshouldatrialfibrillationriskpredictionbeexpandedtoyoungercommunitymembers
AT virdonesaverio validatingriskmodelsversusagealoneforatrialfibrillationinayoungdutchpopulationcohortshouldatrialfibrillationriskpredictionbeexpandedtoyoungercommunitymembers
AT lucassenwimam validatingriskmodelsversusagealoneforatrialfibrillationinayoungdutchpopulationcohortshouldatrialfibrillationriskpredictionbeexpandedtoyoungercommunitymembers
AT gansevoortront validatingriskmodelsversusagealoneforatrialfibrillationinayoungdutchpopulationcohortshouldatrialfibrillationriskpredictionbeexpandedtoyoungercommunitymembers
AT rienstramichiel validatingriskmodelsversusagealoneforatrialfibrillationinayoungdutchpopulationcohortshouldatrialfibrillationriskpredictionbeexpandedtoyoungercommunitymembers